HIMS shows it's a platform, not just a compounder
$Hims & Hers Health Inc.(HIMS)$ Up 35% pre-market after announcing a deal w/ Novo Nordisk on Wegovy.
The pricing is what's interesting. $599/mo for Wegovy and Ozempic, Mounjaro, and Zepbound are still $1,899/mo. Generic Liraglutide at $299/mo.
HIMS shows it's a platform, not just a compounder.
Image
Image
PS: It could put pressure on others to lower prices and improve access.
This is the power of an aggregator disrupting the old doctor/pharmacy model that had an incentive to keep prices high.
It's not a straight line up, but this is why I own the disruptor, not the disrupted.
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here：
Trade on a Cash Boost Account and enjoy up to 6 months of Commission-Free trading.
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
